AdLip: Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medication

Launched by NATIONAL UNIVERSITY OF SINGAPORE · Sep 23, 2024

Keywords

ClinConnect Summary

The AdLip clinical trial is studying whether a digital health app, supported by a human coach, can help people stick to their cholesterol-lowering medications. This is important for those with high cholesterol levels (hyperlipidemia) who may not be taking their prescribed medications consistently. The researchers believe that using this app will lead to better adherence compared to standard care, which means patients might be more likely to take their medications as directed.

To participate in this study, you need to be between 21 and 84 years old, live in Singapore, and have been prescribed cholesterol medication like statins. It's also important that you have a smartphone or tablet with internet access. If you join the trial, you can expect support through the app and a coach to help you manage your medication routine. However, there are some health conditions that could prevent you from taking part, such as severe kidney or liver disease, or if you are currently pregnant. If you meet the eligibility criteria, this could be a great opportunity to improve your health with the support of technology and personalized coaching.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Between 21 to 84 years old
• • Prescribed statins with or without ezetimibe for hyperlipidaemia.
• • Medication non-adherence as defined by the \"Extent to Non-adherence\" sub-scale of the DOSE Non-Adherence Measure), with a score \> 1 (range from 0-15)
• • Singapore residents (citizens, permanent residents, or long-term pass holders).
• • In possession of a smartphone or tablet with Android or iOS operating systems.
• • Have internet access on their mobile devices.
• Exclusion Criteria:
• • Does not read or understand English. Current use of smartphone medication adherence app(s) that include statins.
• • Concurrent use of PCSK9 Inhibitors in addition to statins and/or ezetimibe
• • Participation in another study that uses medications that could affect lipid levels
• • Severe renal impairment defined as chronic kidney disease stage 4 and above.
• • Severe liver disease (Child-Pugh Class C)
• • Existing muscular-related complaints or diagnoses which may confound adverse event reporting
• • Uncorrected thyroid conditions, especially poorly-controlled hypothyroidism
• • Documented psychiatric diagnosis or history of mental illness or deemed as unable to give informed consent.
• • Currently pregnant, breastfeeding or expecting to get pregnant during the course of the study (1 year).
• • Guarded prognosis with expectant mortality within 12 months or less.